Intelligent Bio Solutions (Nasdaq: INBS) will present at the Webull Biotech Webinar on November 12, 2026, in a virtual session. Doug Heath, Vice President of Global Sales, will speak at 2:00 p.m. ET. The presentation will be followed by a live question-and-answer session.

Click to view the official SEC document.

Intelligent Bio Solutions (INBS) will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET.The moderated discussion will feature President and CEO Harry Simeonidis and Vice President of Product Development Peter Passaris. Topics include the company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, supporting clinical data, the FDA review process, and commercial progress outside the United States. The event will be accessible via live webcast through an online registration link, with a replay available on the company’s investor relations website after the session.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Intelligent Bio Solutions (Nasdaq: INBS) reported results from a multi-site U.S. Method Comparison Study of its Intelligent Fingerprinting Drug Screening System for detecting the opiate codeine. Conducted at three independent clinical sites in pre-employment and workplace settings, the study assessed sensitivity, specificity and accuracy against an LC-MS/MS reference method.The System achieved total accuracy of 98.2%, sensitivity of 94.6%, and specificity of 100% across 214 samples (144 true negatives, 70 true positives, 4 false negatives, 0 false positives). Accuracy and sensitivity improved versus a prior 2024 study, which showed approximately 94% accuracy and 82% sensitivity, while specificity remained at 100%. The data complete the company’s FDA 510(k) clinical package, and Intelligent Bio Solutions now expects to submit its 510(k) application for the System in September 2026, supporting a planned U.S. market entry following potential FDA clearance.

Intelligent Bio Solutions (Nasdaq: INBS) entered a securities purchase agreement with a single existing institutional investor for a private placement priced at-the-market under Nasdaq rules. The company will issue 2,036,659 shares of common stock (or Series M pre-funded warrants), plus Series N-1 and Series N-2 warrants to purchase up to 2,036,659 shares each, at a combined purchase price of $2.455 per share unit, for expected gross proceeds of about $5.0 million before fees.The Series N-1 and N-2 warrants have an exercise price of $2.33 per share. N-1 warrants are exercisable immediately; N-2 warrants become exercisable upon stockholder approval. Both series have five-year terms starting when related resale registration statements are declared effective by the SEC. Subject to certain conditions, the N-1 warrants are callable at the company’s option after it publicly announces FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening System. Closing is expected on or about September 2, 2026, with net proceeds intended for working capital and general corporate purposes.

Click to view the official SEC document.